• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    2/21/25 7:00:26 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $CDIO alert in real time by email
    false 0001870144 0001870144 2025-02-21 2025-02-21 0001870144 CDIO:CommonStockParValue0.00001Member 2025-02-21 2025-02-21 0001870144 CDIO:RedeemableWarrantsEachWarrantExercisableForOnehalfOfOneShareOfCommonStockMember 2025-02-21 2025-02-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

       

    Form 8-K

     

    Current Report

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    February 21, 2025

    Date of Report (Date of earliest event reported)

     

    CARDIO DIAGNOSTICS HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41097   87-0925574
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    311 W. Superior Street, Suite 444, Chicago, IL   60654
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code:  (855) 226-9991

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.00001   CDIO   The Nasdaq Stock Market LLC
    Redeemable Warrants, each warrant exercisable for one share of Common Stock   CDIOW   The Nasdaq Stock Market LLC

     

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

     

     
     

     

    Item 7.01. Regulation FD Disclosure

    Effective February 21, 2025, senior management of Cardio Diagnostics Holdings Inc. (the "Company”) will begin using the materials included in Exhibit 99.1 to this report (the “Investor Presentation”) in connection with presentations to existing and prospective investors. The Investor Presentation is incorporated into this Item 7.01 by this reference and will also be available on the Company's website at www.cardiodiagnosticsinc.com.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit No.   Description of Exhibit
         
    99.1   Cardio Diagnostics Holdings Inc. February 2025 Investor Presentation.
    104   Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

     

    THE INFORMATION CONTAINED IN ITEM 7.01 OF THIS CURRENT REPORT, INCLUDING EXHIBIT 99.1 ATTACHED HERETO, SHALL NOT BE DEEMED "FILED” FOR THE PURPOSES OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, NOR SHALL IT BE DEEMED INCORPORATED BY REFERENCE INTO ANY REGISTRATION STATEMENT OR OTHER FILING PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, EXCEPT AS OTHERWISE EXPRESSLY STATED IN SUCH FILING.

     
     

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Dated:  February 21, 2025 CARDIO DIAGNOSTICS HOLDINGS INC.
       
       By: /s/ Elisa Luqman
        Elisa Luqman
    Chief Financial Officer

     

     

    Get the next $CDIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDIO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CDIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor

      Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor. Dr. Ramjee is a cardiologist and a health innovation leader, serving as the National Co-Chair of Cardiology and Innovation at CommonSpirit Health Enterprise and is also a member of the American Heart Association Board of Directors. The appointment of Dr. Ramjee as a Strategic Advisor to Cardio Diagnostics is a significant development to the Company's continued growth and market expansion. He brings a wealth of experience and proven track record in clinical practice, innovation and research, makin

      1/24/24 8:31:00 AM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Cardio Diagnostics Holdings, Inc. Appoints Biotechnology Investor, Executive & Serial Entrepreneur Paul Burton to its Board of Directors

      Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director. Mr. Burton will Chair the Nominating and Corporate Governance Committee and will also serve as a member of the Audit Committee. Mr. Burton is the Managing Partner at 2Flo Ventures, an early-stage healthcare investor and startup studio focused on accelerating health equity. He is also the CEO of Akan Biosciences, a clinical-stage biotech company, and runs an advisory firm working closely with healthcare growth companies. Mr. Burton brings over 20 years of experience in medical

      12/21/23 9:21:00 AM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CDIO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Cardio Diagnostics Holdings Inc.

      10-Q - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

      5/15/25 4:20:23 PM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

      5/13/25 8:00:25 AM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-8 filed by Cardio Diagnostics Holdings Inc.

      S-8 - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

      4/8/25 4:30:37 PM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CDIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CDIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CDIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Cardio Diagnostics Broadens Access to Precision Cardiovascular Care with New Practice Partnerships Across U.S. Mainland and Puerto Rico

      Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), a pioneer in AI-powered precision cardiovascular medicine, today announced the continued expansion of its reach with a new cohort of healthcare practices across the United States now offering its innovative clinical blood tests, Epi+Gen CHD™ and PrecisionCHD™. This group of adopters spans a wide range of care models - from concierge and direct primary care to functional and integrative medicine, demonstrating the growing appetite for proactive, personalized cardiovascular care. These latest adopters are primarily independent practices deeply committed to modernizing the patient experience and championing heart disease prevention and early d

      5/20/25 8:35:00 AM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split

      Cardio Diagnostics Holdings, Inc. ("Cardio" or the "Company") (NASDAQ:CDIO), today announced a 1-for-30 reverse stock split of its common stock effective with the market opening on May 13, 2025. The reverse stock split will take effect at 11:59 pm Eastern Time on May 12, 2025, and the Company's common stock will open for trading on The Nasdaq Capital Market on May 13, 2025 on a post-split basis, under the existing ticker symbol "CDIO" but with new CUSIP number 14159C202. The reverse stock split is part of the Company's plan to regain compliance with the minimum bid price requirement for the continued listing on The Nasdaq Capital Market. The reverse split was authorized by the Company's s

      5/8/25 8:35:00 AM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session

      Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced its participation in the American College of Cardiology's 74th Annual Scientific Session & Expo (ACC.25), taking place March 29-31, 2025, at McCormick Place in Chicago, IL. Cardio Diagnostics will be exhibiting at Booth #2033, showcasing its growing portfolio of advanced cardiovascular solutions, focusing on the Company's PrecisionCHD™ test and its enhanced Actionable Clinical Intelligence (ACI™) report designed to transform how coronary heart disease (CHD) is diagnosed and managed. Cardio Diagnostics' mission is to redefine cardiovascular care by combining epigenetics,

      3/26/25 8:31:00 AM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Cardio Diagnostics Holdings Inc. (Amendment)

      SC 13G/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)

      5/8/24 2:22:56 PM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Director Fung Peter K

      4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

      4/1/25 1:19:48 PM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Director Betts Wendy J

      4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

      4/1/25 1:17:06 PM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Director Burton Paul Frederick

      4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

      4/1/25 12:54:12 PM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CDIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Technology Officer Dogan Timur bought $20,000 worth of shares (68,965 units at $0.29) (SEC Form 4)

      4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

      10/9/24 1:18:30 PM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: Chief Executive Officer Dogan Meeshanthini bought $20,000 worth of shares (68,965 units at $0.29) (SEC Form 4)

      4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

      10/8/24 10:42:31 AM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: Chief Executive Officer Dogan Meeshanthini bought $20,000 worth of shares (68,965 units at $0.29) (SEC Form 4)

      4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

      10/7/24 11:29:46 AM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care